Causes and consequences of lipoprotein(a) abnormalities in kidney disease

Clinical and Experimental Nephrology

Volumn 18, Issue 2, 2014, Pages 234-237

  Kronenberg, Florian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Apolipoprotein(a); Cardiovascular disease; Chronic kidney disease; Genetics; Lipoprotein(a); Risk factor

Indexed keywords

LIPOPROTEIN A;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHRONIC KIDNEY DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALNUTRITION; MENDELIAN RANDOMIZATION ANALYSIS; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; PROTEIN METABOLISM; PROTEINURIA; REVIEW; RISK FACTOR; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LIPOPROTEIN(A); NEPHROTIC SYNDROME; PROTEINURIA; RENAL DIALYSIS; RISK FACTORS;

EID: 84899987498     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0875-8     Document Type: Review

References (35)

1. Kronenberg F, Utermann G. Lipoprotein(a) - resurrected by genetics. J Intern Med. 2013;273:6-30.
2. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80:458-65.
3. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412-23.
4. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-26.
5. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-14.
6. Kraft HG, Lingenhel A, Köchl S, et al. Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16:713-9. (Pubitemid 26179358)
7. Erqou S, Thompson A, Di AE, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55:2160-7.
8. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein[a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230-9.
9. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788-95. (Pubitemid 47207175)
10. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck Study. J Am Coll Cardiol. 2006;47:2219-28. (Pubitemid 43795077)
11. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56:946-55.
12. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol. 2008;19:369-77.
13. Kronenberg F, Trenkwalder E, Lingenhel A, et al. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J Lipid Res. 1997;38:1755-63. (Pubitemid 27411267)
14. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98:2414-24. (Pubitemid 26394218)
15. Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol. 1996;16:905-11. (Pubitemid 26266886)
16. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11:105-15. (Pubitemid 30020432)
17. Dieplinger H, Lackner C, Kronenberg F, et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest. 1993;91:397-401. (Pubitemid 23064119)
18. Kronenberg F, König P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110-20.
19. Stenvinkel P, Heimbürger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 1998;53:1336-42. (Pubitemid 28316895)
20. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-58. (Pubitemid 29082891)
21. Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med. 1993;119:263-9. (Pubitemid 23319881)
22. Kronenberg F, Lingenhel A, Lhotta K, et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int. 2004;65:606-12. (Pubitemid 38130655)
23. Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007;71:1036-43. (Pubitemid 46741981)
24. De Sain-van der Velden MGM, Reijngoud DJ, Kaysen GA, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol. 1998;9:1474-81. (Pubitemid 28354558)
25. Kronenberg F, König P, Lhotta K, et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb. 1994;14:1399-404.
26. Kronenberg F, Lhotta K, König P, Margreiter R, Dieplinger H, Utermann G. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. Eur J Hum Genet. 2003;11:693-9. (Pubitemid 37160991)
27. Kerschdorfer L, König P, Neyer U, et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis. 1999;144:381-91. (Pubitemid 29305472)
28. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252-60.
29. Lamina C, Kronenberg F. The mysterious lipoprotein(a) is still good for a surprise. Lancet Diabetes Endocrinol. 2013. doi:10.1016/S2213-8587(13)70085-8.
30. Kamstrup PR, Nordestgaard BG. Lipoprotein(a) levels, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013. doi:10.1016/S2213-8587(13)70064-0.
31. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992;86:475-82.
32. Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027-36. (Pubitemid 29203090)
33. Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246-61. (Pubitemid 46536911)
34. Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the Choice Study. Circulation. 2002;106:2812-8. (Pubitemid 35396981)
35. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol. 2005;16:1794-802. (Pubitemid 41716486)